Rebif

2015 set to be a transitional year for Merck KGaA's health unit

down sales of its injectable multiple sclerosis (MS) drug Rebif (interferon beta-1a). ... Rebif sales fell nearly 16% to 430m as the MS market continues to switch towards oral therapies such as Biogen Idec's Tecfidera (dimethyl glutamate) and Novartis'

Sanofi persuades FDA to back its MS drug Lemtrada

Merck Serono's Rebif (interferon beta-1a). ... Lemtrada demonstrated superior efficacy over Rebif on annualised relapse rates in the two studies which were the basis for approval.”.

FDA approves Biogen Idec's long-acting MS therapy

The new long-acting formulation will give Biogen Idec a competitive advantage over interferon rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon

Rebif hit again as competition bites

Sales of Merck Serono's flagship multiple sclerosis drug Rebif (interferon beta-1a) were once again dragged down by fierce competition in the second quarter of 2014. ... Rebif's figures include negative exchange rate effects, and Merck insists that

Plegridy approval underlines Biogen Idec's dominance in MS

Plegridy's dosing gives Biogen Idec a competitive advantage over Avonex rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon beta-1a), and

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]